



Paris, October 23, 2025.

LISI Group has entered into an agreement with SK CAPITAL for the sale of the LISI MEDICAL division

Further to the press release dated July 9, 2025, following the opinions issued by the employees representative bodies of the French entities concerned and the authorization granted by the LISI Board of Directors on October 23, 2025, LISI Group (Euronext Paris ISIN code FR0000050353 – FII) has entered into a binding agreement with the American company SK CAPITAL for the sale of the LISI MEDICAL division (meaning LISI MEDICAL - Head office in Neyron, LISI MEDICAL ORTHOPAEDICS - Caen, LISI MEDICAL FASTENERS - Neyron and LISI MEDICAL REMMELE - Minneapolis US).

LISI MEDICAL is specializing in medical device subcontracting, particularly orthopedic implants and minimally invasive surgery instruments. The division produces and packages machined products in titanium, chrome-cobalt and high-technology stainless steel for joint reconstruction (hip, knee, shoulder), traumatology, spine and minimally invasive surgery.

With €185.3M in sales revenue in 2024 and 857 employees distributed between France and the United States (with 2 production sites in each country), LISI MEDICAL positions itself as a global partner offering a complete "more than a part" solution, from raw materials to finished products that are sterilized and packaged, ready for the operating room.

The division actively supports major medical equipment manufacturers (OEMs) in their growth through its recognized industrial expertise, innovation capacity and certified quality standards.

This proposed transaction will enable LISI MEDICAL to benefit fully from SK CAPITAL's support in deploying its strategy, both in terms of organic growth and acquisitions.

Subject to obtaining the final approvals usually required, the transaction is expected to be finalized during the fourth quarter of 2025.

Contact LISI

Emmanuel VIELLARD

Tel.: +33 (0)3 84 57 00 77

Email: emmanuel.viellard@lisi-group.com

Website: www.lisi-group.com

SK CAPITAL

Jeremy MILNER (Gregory FCA)

Tel.: +1 202 401-862-9422

Email: milner@gregoryfca.com Site

Website: www.skcapitalpartners.com

LISI shares are listed on Euronext, compartment A, and are included in the CAC® AERO & DEF., CAC® All Shares, and CAC® Industrials indices, under ISIN code: FR 0000050353.

Reuters code: GFII.PA / Bloomberg code: FII FP

LISI is a global industrial group with sales of nearly €1.8 billion in 2024 and a workforce of 10,262 people. It specializes in the manufacture of high value-added assembly solutions and components for the aerospace, automotive, and medical sectors. As a partner to the world's leading players and driven by long-standing family values, LISI innovates and invests in research and development for the products of tomorrow in order to meet its customers' needs, particularly in terms of quality, safety, and performance. The LISI Group stands out by relying on two strategic pillars: innovation and operational excellence, while integrating a strong CSR culture.

For more information, visit www.lisi-group.com

SK CAPITAL is a transformational private investment firm with a disciplined focus on the specialty materials, ingredients, and life sciences sectors. The firm seeks to build resilient, sustainable, and growing businesses that create substantial long-term value. SK CAPITAL aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK CAPITAL currently has approximately \$10 billion in assets under management as of December 31, 2024.

For more information, visit www.skcapitalpartners.com